4D Molecular Therapeutics (FDMT) Projected to Post Earnings on Thursday

4D Molecular Therapeutics (NASDAQ:FDMT) is expected to release its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect 4D Molecular Therapeutics to post earnings of ($0.97) per share and revenue of $2.5880 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of ($0.53) by $0.96. The firm had revenue of $85.09 million during the quarter, compared to analyst estimates of $30.86 million. 4D Molecular Therapeutics had a negative return on equity of 31.75% and a negative net margin of 164.43%. On average, analysts expect 4D Molecular Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

4D Molecular Therapeutics Trading Up 3.7%

Shares of FDMT traded up $0.36 during trading hours on Wednesday, hitting $10.07. The company had a trading volume of 100,963 shares, compared to its average volume of 750,930. The company has a market capitalization of $526.46 million, a PE ratio of -4.16 and a beta of 2.77. 4D Molecular Therapeutics has a one year low of $3.00 and a one year high of $12.34. The company’s fifty day moving average price is $9.37 and its two-hundred day moving average price is $9.49.

Wall Street Analyst Weigh In

FDMT has been the subject of several recent analyst reports. Jefferies Financial Group reiterated a “buy” rating and set a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Monday, April 20th. Chardan Capital reiterated a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Wall Street Zen upgraded shares of 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, Barclays began coverage on 4D Molecular Therapeutics in a research report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $31.25.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Wexford Capital LP acquired a new position in 4D Molecular Therapeutics during the 3rd quarter valued at approximately $41,000. Daiwa Securities Group Inc. increased its stake in 4D Molecular Therapeutics by 3,362.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after purchasing an additional 6,186 shares in the last quarter. Susquehanna Portfolio Strategies LLC acquired a new position in shares of 4D Molecular Therapeutics in the fourth quarter valued at about $77,000. Martingale Asset Management L P increased its holdings in shares of 4D Molecular Therapeutics by 12.4% in the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock valued at $88,000 after purchasing an additional 1,303 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of 4D Molecular Therapeutics in the first quarter valued at about $39,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.